In vivo CAR-T can solve the delivery problem – but solid tum...
A new generation of in vivo CAR-T cell technologies promises to remove some of the biggest practical barriers to conventional cell therapy.
Newsletters and Deep Dive digital magazine
A new generation of in vivo CAR-T cell technologies promises to remove some of the biggest practical barriers to conventional cell therapy.
Allogeneic CAR-T, built from healthy donor T-cells, offers a different path toward scale, accessibility, and consistency.
Patients will only benefit from a health breakthrough if HCPs and the systems around them are able to put it into practice.
Agentic Call Reports help turn field observations into scalable, actionable insights generating Commercial Evidence.
An AI system can be cheap to buy and expensive to stop.
Editor's Picks
Newsletters and Deep Dive
digital magazine